

					
						November 2, 2017 - By Kurt Siggers
 Analysts expect Nuvo Pharmaceuticals Inc (TSE:NRI) to report $0.07 EPS on November, 9.They anticipate $0.03 EPS change or 30.00% from last quarter’s $0.1 EPS. T_NRI’s profit would be $808,509 giving it 14.61 P/E if the $0.07 EPS is correct. After having $-0.02 EPS previously, Nuvo Pharmaceuticals Inc’s analysts see -450.00% EPS growth. It closed at $4.09 lastly. It is down 0.00% since November 2, 2016 and is . It has underperformed by 16.70% the S&P500.Among 3 analysts covering Mitsubishi UFJ Financial Group (NYSE:MTU), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Mitsubishi UFJ Financial Group had 5 analyst reports since August 17, 2015 according to SRatingsIntel. The company was upgraded on Tuesday, February 21 by Citigroup. The rating was downgraded by Citigroup to “Sell” on Thursday, February 4. The stock of Mitsubishi UFJ Financial Group Inc (ADR) (NYSE:MTU) has “Buy” rating given on Thursday, February 25 by UBS. The firm earned “Neutral” rating on Wednesday, November 23 by Goldman Sachs. The firm has “Hold” rating by Zacks given on Monday, August 17. See Mitsubishi UFJ Financial Group Inc (ADR) (NYSE:MTU) latest ratings:Mitsubishi UFJ Financial Group, IncIt closed at $6.8 lastly. It is down 31.09% since November 2, 2016 and is uptrending. It has outperformed by 14.39% the S&P500.Nuvo Pharmaceuticals Inc., formerly Nuvo Research Inc., is a Canada healthcare company. The company has market cap of $47.24 million. The Firm offers a range of commercial products, including Pennsaid 2%, Pennsaid and the heated lidocaine/tetracaine patch. It has a 9.81 P/E ratio. The Company’s Pennsaid 2% is a non-steroidal anti-inflammatory drug (NSAID) containing 2% diclofenac sodium.Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.By1 Kurt Siggers



(adsbygoogle = window.adsbygoogle || []).push({});
